| 1 |
34763650 | Opposite effects of the triple target (DNA-PK/PI3K/mTOR) inhibitor PI-103 on the radiation sensitivity of glioblastoma cell lines proficient and deficient in DNA-PKcs. | 2021 Nov 11 |
2 |
| 2 |
30943918 | Differential effects of the Akt inhibitor MK-2206 on migration and radiation sensitivity of glioblastoma cells. | 2019 Apr 3 |
1 |
| 3 |
28704425 | In vitro nuclear magnetic resonance spectroscopy metabolic biomarkers for the combination of temozolomide with PI3K inhibition in paediatric glioblastoma cells. | 2017 |
1 |
| 4 |
27224913 | Dual PI3K- and mTOR-inhibitor PI-103 can either enhance or reduce the radiosensitizing effect of the Hsp90 inhibitor NVP-AUY922 in tumor cells: The role of drug-irradiation schedule. | 2016 Jun 21 |
1 |
| 5 |
27380966 | Real-time monitoring of hypertrophy in HL-1 cardiomyocytes by impedance measurements reveals different modes of growth. | 2016 Oct |
1 |
| 6 |
27464548 | [A dual PI3K/mTOR inhibitor, PI-103, cooperates with TRAIL in laryngeal squamous carcinoma cells in vitro]. | 2016 Jul 19 |
1 |
| 7 |
25721419 | β-TrCP1 degradation is a novel action mechanism of PI3K/mTOR inhibitors in triple-negative breast cancer cells. | 2015 Feb 27 |
1 |
| 8 |
26121251 | A Potential Role for the Inhibition of PI3K Signaling in Glioblastoma Therapy. | 2015 |
1 |
| 9 |
24667972 | Reduced Warburg effect in cancer cells undergoing autophagy: steady- state 1H-MRS and real-time hyperpolarized 13C-MRS studies. | 2014 |
1 |
| 10 |
24695632 | Synergistic effects of targeted PI3K signaling inhibition and chemotherapy in liposarcoma. | 2014 |
1 |
| 11 |
25084455 | Lactate and choline metabolites detected in vitro by nuclear magnetic resonance spectroscopy are potential metabolic biomarkers for PI3K inhibition in pediatric glioblastoma. | 2014 |
1 |
| 12 |
25400422 | Inhibition of PI3K/Akt/mTOR signaling pathway enhances the sensitivity of the SKOV3/DDP ovarian cancer cell line to cisplatin in vitro. | 2014 Oct |
1 |
| 13 |
22488590 | Inhibition of constitutively activated phosphoinositide 3-kinase/AKT pathway enhances antitumor activity of chemotherapeutic agents in breast cancer susceptibility gene 1-defective breast cancer cells. | 2013 Sep |
1 |
| 14 |
23038273 | PI3K/mTOR inhibition upregulates NOTCH-MYC signalling leading to an impaired cytotoxic response. | 2013 Mar |
3 |
| 15 |
23243017 | Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism. | 2013 Feb 15 |
1 |
| 16 |
23378341 | FOXO3a is a major target of inactivation by PI3K/AKT signaling in aggressive neuroblastoma. | 2013 Apr 1 |
1 |
| 17 |
23684925 | Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma. | 2013 Sep 1 |
1 |
| 18 |
22573716 | Sensitivity of glioblastomas to clinically available MEK inhibitors is defined by neurofibromin 1 deficiency. | 2012 Jul 1 |
1 |
| 19 |
21048785 | Vertical inhibition of the mTORC1/mTORC2/PI3K pathway shows synergistic effects against melanoma in vitro and in vivo. | 2011 Feb |
2 |
| 20 |
21084267 | A dual PI3K/mTOR inhibitor, PI-103, cooperates with stem cell-delivered TRAIL in experimental glioma models. | 2011 Jan 1 |
1 |
| 21 |
21266843 | Autophagy and Akt promote survival in glioma. | 2011 May |
2 |
| 22 |
21636709 | Control of proliferation in astrocytoma cells by the receptor tyrosine kinase/PI3K/AKT signaling axis and the use of PI-103 and TCN as potential anti-astrocytoma therapies. | 2011 Jun |
1 |
| 23 |
19810100 | The dual PI3K/mTOR inhibitor PI-103 promotes immunosuppression, in vivo tumor growth and increases survival of sorafenib-treated melanoma cells. | 2010 Apr 1 |
3 |
| 24 |
20179189 | Drugging the PI3 kinome: from chemical tools to drugs in the clinic. | 2010 Mar 15 |
2 |
| 25 |
20551061 | The phosphoinositide 3-kinase inhibitor PI-103 downregulates choline kinase alpha leading to phosphocholine and total choline decrease detected by magnetic resonance spectroscopy. | 2010 Jul 1 |
1 |
| 26 |
21062993 | Akt and autophagy cooperate to promote survival of drug-resistant glioma. | 2010 Nov 9 |
1 |
| 27 |
21187475 | PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways. | 2010 Dec |
4 |
| 28 |
19177002 | Molecular pharmacology of phosphatidylinositol 3-kinase inhibition in human glioma. | 2009 Feb 1 |
2 |
| 29 |
19351820 | Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia. | 2009 Apr 15 |
3 |
| 30 |
19383916 | Relationship of deregulated signaling converging onto mTOR with prognosis and classification of lung adenocarcinoma shown by two independent in silico analyses. | 2009 May 1 |
2 |
| 31 |
19513541 | A novel dual PI3Kalpha/mTOR inhibitor PI-103 with high antitumor activity in non-small cell lung cancer cells. | 2009 Jul |
3 |
| 32 |
19528441 | Combination of PI3K/mTOR inhibition demonstrates efficacy in human chordoma. | 2009 Jun |
3 |
| 33 |
18548093 | The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML. | 2008 Sep |
1 |
| 34 |
18548104 | PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML. | 2008 Sep |
3 |
| 35 |
18922908 | Dual inhibition of PI3Kalpha and mTOR as an alternative treatment for Kaposi's sarcoma. | 2008 Oct 15 |
2 |
| 36 |
16697955 | A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. | 2006 May |
1 |